Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

Item

http://www.wikidata.org/entity/Q39443721

Q39443721

about

Epigenetics in non-small cell lung cancer: from basics to therapeutics Epigenetic treatment of solid tumours: a review of clinical trials Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding Trial Watch: Proteasomal inhibitors for anticancer therapy Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1 Natural products from mangrove actinomycetes.Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects Combination therapy in combating cancer.Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo Marine-derived angiogenesis inhibitors for cancer therapy.Evaluation of surrogate tissues as indicators of drug activity in a melanoma skin model Targeting ubiquitination for cancer therapies.Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies Emerging therapies targeting the ubiquitin proteasome system in cancer Finding chemo: the search for marine-based pharmaceutical drugs active against cancer.Microbial natural products: molecular blueprints for antitumor drugs.Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).An analysis of the safety profile of proteasome inhibitors for treating various cancers.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Role of the ubiquitin proteasome system in hematologic malignancies.Anticancer agent-based marine natural products and related compounds.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.Bronchial biopsy specimen as a surrogate for DNA methylation analysis in inoperable lung cancer.Positioning of proteasome inhibitors in therapy of solid malignancies.The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities.

P2860

Q26749113-E2B7C75A-A076-4B53-B58F-267280919AA1 Q26773803-2ED3629B-A90C-408E-998B-1584189E1BCF Q26776294-7F267F32-7C64-45B7-ADBC-E36D3C830AB3 Q26799714-B36955D5-21DE-4E23-9E0F-9D9C37DBA12B Q27677425-FA876930-E439-48B3-9647-2FF9F7A7FB8F Q28082910-7699D3A9-9580-4209-BD91-2C346E2E5353 Q33566645-D2247EB7-13CC-448D-9B7F-23120DF3F02D Q33627312-78A17044-5B41-4A11-8DF2-4C955A7A05AF Q33736692-D315590D-3F97-436D-82CD-02730D66BE0A Q33801377-8CA7EB09-6142-41A1-9E35-39C13E0A3806 Q33914234-CC67B5DD-15ED-4F7C-B26E-4028E5B813CD Q34213967-3188292D-912C-4273-BEB1-9AD47C84BE4B Q34534191-BA32C276-6AB0-4EE5-9C0E-F34CA8AEF423 Q35044051-FC978D29-7984-4EB7-95E7-AA24E184AC3C Q35214924-99B383CB-AC40-4F3E-B28C-C16AEB7D70B7 Q35969785-DDF3F715-39A2-4E6A-BAFC-1B31D72854E8 Q36109506-6FBEF015-C467-4F28-B96F-5CCAAC00F9BF Q36500531-1D22F5A6-577D-40DC-823C-11A0E8329BB5 Q36994177-DB8BD29F-348D-4B37-8AB3-2E0445597F24 Q37148914-41D879D9-34F0-4333-A36D-F53744AE1939 Q37158445-54FA450E-752E-485F-B58C-BA4FDA595EB4 Q37226511-58957A89-3887-4DA2-BD9A-FD6E2EACCA20 Q37410632-76F2C6C3-E2A9-441D-85EA-0DCE42615C49 Q38127449-551D2541-8457-42E0-B23D-D6B549D5F0D4 Q38133765-6859F76E-AB7C-4984-AA85-7812983841C2 Q38219616-BE88AAC2-BDEF-4B5A-A4F9-2959E374831E Q38227506-0926117E-69C1-4D1A-A7C8-706CF72CBE81 Q38240733-7F2F2034-0315-4907-943C-7260E4903ECE Q38289055-3E0A3ADA-BBC8-4829-A615-B07D9149E2FF Q38307526-4D62EBAD-8818-4BAA-BEC3-4D925CEF4C3C Q38525073-69EA84A2-F4D9-44DF-9EA7-CC0BF32273AB Q38582589-EE97A1B7-547F-4D4B-8B41-FBF7FC9D7BB5 Q38993736-4C76995E-0D9C-4E53-9199-5358A0B4F575 Q39184898-5CC5CEBF-9EE8-4D83-8B35-3FDD0E230A68 Q39204274-4CBC4A1A-A732-4A98-9A01-819B53EEA172 Q41184318-7CD62DF0-BA14-44C8-A0A3-40CF55E67C7C Q41607725-CD3A36F8-3FC5-44CE-BEED-9097F478412D Q47107660-86480801-1D67-4CFA-A45D-E509A65E9E4F Q47353792-B59F815C-0821-4D9B-91AD-9C464C7C4FC5 Q48000346-B2FDD66F-9797-4964-BE66-775873F13738

P2860

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

Item

http://www.wikidata.org/entity/Q39443721

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Phase 1 clinical trial of the ...... ssessments of the combination.

@en

Phase 1 clinical trial of the ...... ssessments of the combination.

@nl

type

Item

label

Phase 1 clinical trial of the ...... ssessments of the combination.

@en

Phase 1 clinical trial of the ...... ssessments of the combination.

@nl

prefLabel

Phase 1 clinical trial of the ...... ssessments of the combination.

@en

Phase 1 clinical trial of the ...... ssessments of the combination.

@nl

P1476

Phase 1 clinical trial of the ...... ssessments of the combination.

@en

P2093

Amanda Townsend

http://www.w3.org/2001/XMLSchema#string

Ana Lay

http://www.w3.org/2001/XMLSchema#string

Andrew Spencer

http://www.w3.org/2001/XMLSchema#string

Angie Longenecker

http://www.w3.org/2001/XMLSchema#string

Christopher Sweeney

http://www.w3.org/2001/XMLSchema#string

David J McConkey

http://www.w3.org/2001/XMLSchema#string

G Kenneth Lloyd

http://www.w3.org/2001/XMLSchema#string

Girish Sharma

http://www.w3.org/2001/XMLSchema#string

Harry A Drabkin

http://www.w3.org/2001/XMLSchema#string

Lonnie Lee

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.

Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products.

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.

P2888

s10637-011-9766-6

P304

2303-2317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-011-9766-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22080430

http://www.w3.org/2001/XMLSchema#string

P921

patient

phase I clinical trial

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

about

P2860

P2860

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921